Protective role of AGK2 on thioacetamide-induced acute liver failure in mice

Area of Science:

• Hepatology and Pharmacology
• Molecular Biology and Immunology

Background:

• Acute liver failure (ALF) poses significant clinical challenges with limited treatment options.
• Thioacetamide (TAA) is a common inducer of ALF in preclinical models, mimicking human liver injury.
• Sirtuin 2 (SIRT2) is implicated in cellular stress responses and inflammation, making it a potential therapeutic target.

Purpose of the Study:

• To investigate the protective effects of AGK2, a selective SIRT2 inhibitor, against TAA-induced ALF in mice.
• To elucidate the underlying mechanisms of AGK2's protective action, focusing on inflammatory and apoptotic pathways.

Main Methods:

• Male C57BL/6 mice were divided into control, TAA, AGK2 + TAA, and AGK2 groups.
• Liver damage was assessed via histology (HE staining), apoptosis (TUNEL), and liver function enzymes (ALT, AST).
• Inflammatory markers (iNOS, TNF-α, IL-1β) and signaling pathways (MAPK, NF-κB) were analyzed using Western blotting and RT-PCR.

Main Results:

• AGK2 treatment significantly improved liver pathology and function in TAA-induced ALF mice.
• AGK2 administration reduced pro-inflammatory cytokine levels and suppressed NF-κB and MAPK pathway activation.
• Pretreatment with AGK2 enhanced survival rates and alleviated hepatocyte apoptosis.

Conclusions:

• AGK2 demonstrates significant protective effects in a mouse model of ALF, improving survival and mitigating liver damage.
• The mechanism involves the suppression of inflammatory responses via inhibition of MAPK and NF-κB signaling pathways.
• Pharmacological inhibition of SIRT2 presents a promising therapeutic avenue for treating acute liver failure.